CircuLex CML-HSA/Nε-(Carboxymethyl)lysine-HSA
| Code | Size | Price |
|---|
| MBL-CY-R2066 | 200 ug | £285.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
dry ice
Storage:
-20°C
Documents
Further Information
Background:
Reducing sugars react with protein amino groups to form a diverse
group of protein-bound moieties with fluorescent and cross-linking
properties. These compounds, called advanced glycosylation end
products (AGEs), have been implicated in the structural and
functional alterations of proteins that occur during aging and
long-term diabetes.
Although several AGE structures have been reported (1, 2), it was
demonstrated that Nε-(carboxymethyl) lysine (CML) is a major
antigenic AGE structure. CML concentration is also increased in
patients who have diabetes with complications, including
nephropathy (3?5), retinopathy (6), and atherosclerosis (7?9). CML
is also recognized by receptor for AGE (RAGE), and CML-RAGE
interaction activates cell signaling pathways such as NF-κB and
enhances the expression of vascular cell adhesion molecule-1 in
human umbilical vein endothelial cells (10).
Concentration:
1.0 mg/mL
Formulation:
The CML-HSA /Nε-(carboxymethyl) lysine-HSA is supplied frozen
in a buffer containing 10mM PBS (pH 7.2).
Gene IDs:
Human: 5444 Mouse: 18979
Shelf Life:
1 year
References
(1) Ikeda K, et al.: Biochemistry 35: 8075 ?8083, 1996
(2) Reddy S, et al.: Biochemistry 34: 10872 ?10878, 1995
(3) Makino H, et al.: Kidney Int. 48: 517 ?526, 1995 (4) Suzuki D, et al.: J Diabetes Complications 10: 314 ?319, 1996
(5) Imai N, et al.: Nephron 76: 153 ?160, 1997
(6) Murata T, et al.: Diabetologia 40: 764 ?769, 1997
(7) Kume S, Takeya et al.: Am J Pathol. 147: 654 ?667, 1995
(8) Sakata N, et al.: Atherosclerosis 141: 61 ?75, 1998
(9) Sakata N, et al.: Atherosclerosis 142: 67 ?77, 1999
(10) Kislinger T, et al.: J. Biol. Chem. 274: 31740 ?31749, 1999